Differences in efficacy on substance abuse between risperidone and clozapine supports the importance of differential modulation of dopaminergic neurotransmission

Psychopharmacology Bulletin

Volumn 42, Issue 4, 2009, Pages 40-52

  Machielsen, Marise W J ^a   De Haan, Lieuwe ^b  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Clozapine; Dopamine D1 eceptor; Dopamine D2 receptor; Risperidone; Substance related disorders

Indexed keywords

CLOZAPINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; PLACEBO; RISPERIDONE;

CLINICAL TRIAL; DOPAMINERGIC SYSTEM; DRUG DEPENDENCE; DRUG DEPENDENCE TREATMENT; DRUG EFFECT; DRUG EFFICACY; HUMAN; NEUROTRANSMISSION; REVIEW; SUBSTANCE ABUSE; TREATMENT RESPONSE;

ANTIPSYCHOTIC AGENTS; CLOZAPINE; HUMANS; PSYCHOTIC DISORDERS; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2; RISPERIDONE; SUBSTANCE-RELATED DISORDERS;

EID: 79952999498     PISSN: 00485764     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. Regier DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA. 1990;264(19):2511-2518.
2. Dixon L. Dual diagnosis of substance abuse in schizophrenia: prevalence and impact on outcomes. Schizophr Res. 1999;35 Suppl:S93-100.
3. Linszen DH, Dingemans PM, Lenior ME. Cannabis abuse and the course of recent-onset schizophrenic disorders. Arch Gen Psychiatry. 1994;51(4):273-279. (Pubitemid 24127299)
4. Volkow ND, Fowler JS, Wang GJ, Swanson JM. Dopamine in drug abuse and addiction: results from imaging studies and treatment implications. Mol Psychiatry. 2004;9(6):557-569. (Pubitemid 38850435)
5. Dagher A, Bleicher C, Aston JA, Gunn RN, Clarke PB, Cumming P. Reduced dopamine D1 receptor binding in the ventral striatum of cigarette smokers. Synapse. 2001;42(1):48-53. (Pubitemid 32786423)
6. Volkow ND, Fowler IL. Addiction, a disease of compulsion and drive: involvement of the orbitofrontal cortex. Cerebral Cortex. 2000;10:318-325. (Pubitemid 30159298)
7. Goldstein RZ, Tomasi D, Alia-Klein N, et al. Subjective sensitivity to monetary gradients is associated with frontolimbic activation to reward in cocaine abusers. Drug and alcohol dependence. 2007;87(2-3):233-240. (Pubitemid 46215930)
8. Green AI, Noordsy DL, Brunette MF, O'Keefe C. Substance abuse and schizophrenia: pharmacotherapeutic intervention. Journal of Substance Abuse Treatment. 2008;34:61-71. (Pubitemid 350216350)
9. de Haan L, Lavalaye J, Linszen D, Dingemans PM, Booij J. Subjective experience and striatal dopamine D(2) receptor occupancy in patients with schizophrenia stabilized by olanzapine or risperidone. Am J Psychiatry. 2000;157(6):1019-1020.
10. 2 receptor occupancy in patients with recent-onset schizophrenia treated with low-dose olanzapine or haloperidol: a randomized, double-blind study. Am J Psychiatry. 2003;160(2):303-309.
11. 2 receptors: a PET study in schizophrenia. Am J Psychiatry. 2007;164(4):630-637.
12. Wobrock T, Soyka M. Pharmacotherapy of schizophrenia with comorbid substance use disorder - reviewing the evidence and clinical recommendations. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(6):1375-1385.
13. Smelson DA, Dixon L, Craig T, et al. Pharmacological treatment of schizophrenia and co-occurring substance use disorders. CNS Drugs. 2008;22(11):903-916.
14. Seeman P. Atypical antipsychotics: mechanism of action. Can J Psychiatry. 2002;47(1):27-38. (Pubitemid 34302921)
15. Green AI, Zimmet SV, Strous RD, Schildkraut JJ. Clozapine for comorbid substance use disorder and schizophrenia: do patients with schizophrenia have a reward-deficiency syndrome that can be ameliorated by clozapine? Harv Rev Psychiatry. 1999;6(6):287-296.
16. Kapur S, Seeman P. Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis. Am J Psychiatry. 2001;158(3):360-369.
17. de Haan L, Booij J, Lavalaye J, van Amelsvoort T, Linszen D. Occupancy of dopamine D2 receptors by antipsychotic drugs is related to nicotine addiction in young patients with schizophrenia. Psychopharmacology (Berl). 2006;183(4):500-505. (Pubitemid 41721152)
18. Kuroki T, Nagao N, Nakahara T. Neuropharmacology of second-generation antipsychotic drugs: a validity of the serotonin-dopamine hypothesis. Prog Brain Res. 2008;172:199-212.
19. 2 receptors with clozapine: differentiation from other atypical antipsychotics. Am J Psychiatry. 2004;161(9):1620-1625.
20. Miller R, Wickens JR, Beninger RJ. Dopamine D-1 and D-2 receptors in relation to reward and performance: a case for the D-1 receptor as a primary site of therapeutic action of neuroleptic drugs. Progress in Neurobiology. 1990;34:143-183. (Pubitemid 20066616)
21. Green AI, Burgess ES, Dawson R, Zimmet SV, Strous RD. Alcohol and cannabis use in schizophrenia: effects of clozapine vs. risperidone. Schizophr Res. 2003;60(1):81-85. (Pubitemid 36015790)
22. Kim JH, Kim D, Marder SR. Time to rehospitalization of clozapine versus risperidone in the naturalistic treatment of comorbid alcohol use disorder and schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(4):984-988. (Pubitemid 351609233)
23. Grabowski J, Rhoades H, Silverman P, et al. Risperidone for the treatment of cocaine dependence: randomized, double-blind trial. J Clin Psychopharmacol. 2000;20(3):305-310. (Pubitemid 30318358)
24. Loebl T, Angarita GA, Pachas GN, et al. A randomized, double-blind, placebo-controlled trial of long-acting risperidone in cocaine-dependent men. J Clin Psychiatry. 2008;69(3):480-486. (Pubitemid 351549404)
25. Smelson DA, Williams J, Ziedonis D, et al. A double-blind placebo-controlled pilot study of risperidone for decreasing cue-elicited craving in recently withdrawn cocaine dependent patients. J Subst Abuse Treat. 2004;27(1):45-49. (Pubitemid 38829778)
26. Albanese MJ, Suh JJ. Risperidone in cocaine-dependent patients with comorbid psychiatric disorders. J Psychiatr Pract. 2006;12(5):306-311. (Pubitemid 44439987)
27. Meredith CW, Jaffe C, Yanasak E, Cherrier M, Saxon AJ. An open-label pilot study of risperidone in the treatment of methamphetamine dependence. J Psychoactive Drugs. 2007;39(2):167-172. (Pubitemid 47105699)
28. Roy A, Roy M, Smelson DA. Risperidone, ERG and cocaine craving. Am J Addict. 1998;7(1):90.
29. Gupta N, Basu D. Does risperidone reduce concomitant substance abuse in cases of schizophrenia? Can J Psychiatry. 2001;46(9):862-863.
30. Tsuang JW, Eckman T, Marder S, Tucker D. Can risperidone reduce cocaine use in substance abusing schizophrenic patients? J Clin Psychopharmacol. 2002;22(6):629-630.
31. George TP, Sernyak MJ, Ziedonis DM, Woods SW. Effects of clozapine on smoking in chronic schizophrenic outpatients. J Clin Psychiatry. 1995;56(8):344-346.
32. Zimmet SV, Strous RD, Burgess ES, Kohnstamm S, Green AI. Effects of clozapine on substance use in patients with schizophrenia and schizoaffective disorder: a retrospective survey. J Clin Psychopharmacol. 2000;20(1):94-98. (Pubitemid 30056360)
33. Procyshyn RM, Tse G, Sin O, Flynn S. Concomitant clozapine reduces smoking in patients treated with risperidone. Eur Neuropsychopharmacol. 2002;12(1):77-80. (Pubitemid 34098834)
34. Albanese MJ, Khantzian EJ, Murphy SL, Green AI. Decreased substance use in chronically psychotic patients treated with clozapine. Am J Psychiatry. 1994;151(5):780-781. (Pubitemid 24140576)
35. Buckley PF. Novel antipsychotic medications and the treatment of comorbid substance abuse in schizophrenia. J Subst Abuse Treat. 1998;15(2):113-116. (Pubitemid 28166627)
36. Marcus P, Snyder R. Reduction of comorbid substance abuse with clozapine. Am J Psychiatry. 1995;152(6):959.
37. Tsuang JW, Eckman TE, Shaner A, Marder SR. Clozapine for substance-abusing schizophrenic patients. Am J Psychiatry. 1999;156(7):1119- 1120.
38. Yovell Y, Opler LA. Clozapine reverses cocaine craving in a treatment-resistant mentally ill chemical abuser: a case report and a hypothesis. J Nerv Ment Dis. 1994;182(10):591-592. (Pubitemid 24318417)
39. Akerele E, Levin FR. Comparison of olanzapine to risperidone in substance-abusing individuals with schizophrenia. Am J Addict. 2007;16(4):260-268. (Pubitemid 47174581)
40. Grabowski J, Rhoades H, Stotts A, et al. Agonist-like or antagonist-like treatment for cocaine dependence with methadone for heroin dependence: two double-blind randomized clinical trials. Neuropsychopharmacology. 2004;29(5):969-981. (Pubitemid 38526797)
41. Levin FR, McDowell D, Evans SM, Brooks D, Spano C, Nunes EV. Pergolide mesylate for cocaine abuse: a controlled preliminary trial. Am J Addict. 1999;8(2):120-127. (Pubitemid 29242237)
42. Rubio G, Martinez I, Ponce G, Jimenez-Arriero MA, Lopez-Munoz F, Alamo C. Long-acting injectable risperidone compared with zuclopenthixol in the treatment of schizophrenia with substance abuse comorbidity. Can J Psychiatry. 2006;51(8):531-539. (Pubitemid 44166341)
43. Smelson DA, Losonczy MF, Davis CW, Kaune M, Williams J, Ziedonis D. Risperidone decreases craving and relapses in individuals with schizophrenia and cocaine dependence. Can J Psychiatry. 2002;47(7):671-675. (Pubitemid 35192034)
44. van Nimwegen LJ, de Haan L, van Beveren NJ, van der Helm M, van den Brink W, Linszen D. Effect of olanzapine and risperidone on subjective well-being and craving for cannabis in patients with schizophrenia or related disorders: a double-blind randomized controlled trial. Can J Psychiatry. 2008;53(6):400-405. (Pubitemid 351878642)
45. Brunette MF, Drake RE, Xie H, McHugo GJ, Green AI. Clozapine use and relapses of substance use disorder among patients with co-occurring schizophrenia and substance use disorders. Schizophr Bull. 2006;32(4):637-643. (Pubitemid 44412851)
46. Combs DR, Advokat C. Antipsychotic medication and smoking prevalence in acutely hospitalized patients with chronic schizophrenia. Schizophr Res. 2000;46(2-3):129-137.
47. Drake RE, Xie H, McHugo GJ, Green AI. The effects of clozapine on alcohol and drug use disorders among patients with schizophrenia. Schizophr Bull. 2000;26(2):441-449. (Pubitemid 30423220)
48. McEvoy J, Freudenreich O, McGee M, VanderZwaag C, Levin E, Rose J. Clozapine decreases smoking in patients with chronic schizophrenia. Biol Psychiatry. 1995;37(8):550-552.
49. McEvoy JP, Freudenreich O, Wilson WH. Smoking and therapeutic response to clozapine in patients with schizophrenia. Biol Psychiatry. 1999;46(1):125-129. (Pubitemid 29296825)
50. Procyshyn RM, Ihsan N, Thompson D. A comparison of smoking behaviours between patients treated with clozapine and depot neuroleptics. Int Clin Psychopharmacol. 2001;16(5):291-294. (Pubitemid 32822449)
51. Wachtel SR, Ortengren A, de WH. The effects of acute haloperidol or risperidone on subjective responses to methamphetamine in healthy volunteers. Drug Alcohol Depend. 2002;68(1):23-33.
52. Rush CR, Stoops WW, Hays LR, Glaser PE, Hays LS. Risperidone attenuates the discriminativestimulus effects of d-amphetamine in humans. J Pharmacol Exp Ther. 2003;306(1):195-204. (Pubitemid 36734373)
53. Newton TF, Ling W, Kalechstein AD, Uslaner J, Tervo K. Risperidone pre-treatment reduces the euphoric effects of experimentally administered cocaine. Psychiatry Res. 2001;102(3):227-233. (Pubitemid 32607561)
54. De La Garza R, Newton TF, Kalechstein AD. Risperidone diminishes cocaine-induced craving. Psychopharmacology (Berl). 2005;178(2-3):347-350.
55. Wines JD, Jr., Weiss RD. Opioid withdrawal during risperidone treatment. J Clin Psychopharmacol. 1999;19(3):265-267. (Pubitemid 29233021)
56. Farren CK, Hameedi FA, Rosen MA, Woods S, Jatlow P, Kosten TR. Significant interaction between clozapine and cocaine in cocaine addicts. Drug Alcohol Depend. 2000;59(2):153-163. (Pubitemid 30417420)
57. Brauer LH, de Wit H. Subjective responses to d-amphetamine alone and after pimozide pretreatment in normal, healthy volunteers. Biol Psychiatry. 1996;39(1):26-32. (Pubitemid 26024199)
58. Brauer LH, deWit H. High dose pimozide does not block amphetamine-induced euphoria in normal volunteers. Pharmacol Biochem Behav. 1997;56(2):265-272.
59. Sherer MA, Kumor KM, Jaffe JH. Effects of intravenous cocaine are partially attenuated by haloperidol. Psychiatry Res. 1989;27(2):117-125. (Pubitemid 19075781)
60. Tiihonen J, Lonnqvist J, Wahlbeck K, et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet. 2009;374(9690):620-627.